Navigation Links
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Date:8/22/2008

9,395 Women Enrolled in Trial Sponsored by Medical Research Council

LEXINGTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for the prevention of HIV and other sexually transmitted infections. The trial is sponsored by the United Kingdom's Medical Research Council (MRC) and conducted by the Microbicides Development Programme (MDP), an international partnership of researchers established to develop microbicides for the prevention of HIV transmission. This trial enrolled 9,395 women at clinics in South Africa, Tanzania, Uganda, and Zambia. Results from this trial are expected to be available by the end of 2009.

This is the second large trial testing the safety and effectiveness of the 0.5% dose of PRO 2000 and the largest trial of any microbicide to date. In July 2007, enrollment of 3,100 women was completed in Protocol HPTN 035 sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Results from the HPTN 035 trial are expected to be available by early 2009.

"The completion of enrollment in this trial marks a significant milestone for Indevus, our shareholders and for women who may benefit from a product that provides a female-controlled option for HIV and STD prevention," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "We have now completed enrollment in two pivotal trials with over 12,000 women participating. If the trials are successful, we expect to be in a position to file marketing applications with regulatory authorities, in
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
6. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Decision Resources Group is launching an extension of ... now include ChinaTrack; the new capabilities track the ... dashboard providing detailed brand-level share tracking and analytics. ChinaTrack ... Other key capabilities of the new line ... to end-user surveys of healthcare facilities, ChinaTrack data is ...
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 /PRNewswire/ ... committee members—who make decisions about which therapies are ... influence formulary placement, according to a new Manhattan ... Makers 2014 . The study finds that P&T ... and pharmacy benefits managers (PBMs) have set a ...
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Touro University California Garners Grant From Long Foundation 2
... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
... 22 Amedisys, a leading home health care and hospice company ... on the future of home care in this week,s issue of ... of the Amedisys Strategic Advisory Board. Titled, "Why ... on the future of home care as an increasingly crucial component ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:7/31/2014)... Atlanta-based Jvion, a leader in clinical ... lessons in predictive population health analytics as part of ... analytics in healthcare. Ritesh Sharma, Jvion COO, commented, “it ... to understand the impact of and potential within predictive ... and a good portion of it is conflicting or ...
(Date:7/31/2014)... During the July 2014 board meeting of the ... executive director of the Mesothelioma Applied Research Foundation, Mary ... promising clinical trials to choose from than ever before. ... have been reporting increased survival and response rates. Some ... is within the field of immunotherapy. One trial, ...
(Date:7/31/2014)... ANN ARBORA new bill introduced in Congress with bipartisan ... from University of Michigan research, which could improve the ... they spend on the medicines and tests they need ... Reps. Diane Black and Earl Blumenauer, grew out of ... with the U-M,s Institute for Healthcare Policy and Innovation. ...
(Date:7/31/2014)... Jacuzzi Luxury Bath, the company ... a new and improved website to meet the needs ... Luxury Bath website has been redesigned to offer a ... represented by the company’s products. The design is current, ... bathroom applications. “The site reflects our Jacuzzi® brand standards, ...
(Date:7/31/2014)... drug, researchers at The Wistar Institute discovered that ... with fewer age-related illnesses. The mice, which lack ... degeneration, obesity, and spontaneous tumor formation when compared ... scientists view the metabolic networks within cells. ... regulator of metabolism and has been shown to ...
Breaking Medicine News(10 mins):Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 3Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 3
... planning to phase out junk food and make exercise mandatory, ... Department to counter childhood obesity//. , ,These recommendations follow ... were being sent to dieticians. , ,The NSW report, ... the biggest study of its kind in the country. The ...
... been awarded with discount shopping cards in return for ... clinic as part of the HIV/AIDS awareness program//. ... Nation's AIDS-prevention agency India has largest number of people, ... virus. ,Sushena Reza-Paul of the Karnataka Health ...
... Pradesh today in protest against dismissal of AIIMS director ... junior doctors observed a `symbolic' strike and a large ... some time condemning the sacking of Venugopal., ,Terming ... the strike was "symbolic and we have no intention ...
... Manchester is reportedly treating patients with mouth and throat cancer ... ,Sources at the Manchester cancer hospital explained that ... doctors at Christie Hospital in Didsbury, Manchester, are planning to ... clinical trail basis. They hope to try and reduce the ...
... expressed their concerns over the practice of "Breast Ironing" ... is used to stunt breast growth in girls by mothers// ... own good. ,It is aimed at warding off ... objects pressed against the developing breasts in teenaged girls. "Breast ...
... is brandishing a piece of his own skull, an ... visitors//. ,The Jawaharlal Nehru Memorial Hospital in Kalyani, ... no less visitors than any museum these days with ... getting electrocuted from a high-voltage wire, holding his own ...
Cached Medicine News:Health News:Man Holds Own Skull in Bengal Medical Miracle 2
Abdominal Binder w / Velcro...
Ideal for abdominal, flank, hip and thigh procedures....
Male high waisted compression girdle with CDIs Wonderfabric™...
This high waist tummy tuck girdle provides the same CDI Wonderfabric™ compression as the 8000 series....
Medicine Products: